{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-011560","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2023-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.963442+00:00","generated_at":"2026-06-17T04:50:25.899137+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"AIM ImmunoTech funds immune monitoring study & hires consultant for pancreatic cancer Ampligen trial","bullets":["Entered $200K grant with Erasmus MC for immune monitoring in pancreatic cancer patients.","Hired Dr. Casper H.J. van Eijck as consultant to recruit European sites for Ampligen pancreatic cancer trials.","Consultant to also introduce COVID, Long COVID & pancreatic cancer studies into Poland.","Consulting fee: up to $2,000/month; aggregate cap of $24,500 after AMP-270 study start."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-011560","json":"https://secwatch.observer/filing/0001493152-23-011560.json","markdown":"https://secwatch.observer/filing/0001493152-23-011560.md","text":"https://secwatch.observer/filing/0001493152-23-011560.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315223011560/0001493152-23-011560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315223011560/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T04:50:25.899137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7082c059f7c893b0fe39a7f6bb2d35513d304195","claim":"AIM ImmunoTech Inc. entered into Unrestricted Grant Agreement with Erasmus University Medical Center (effective 2023-04-04).","evidence_excerpt":"On April 4, 2023, AIM ImmunoTech Inc. (the “Company”) executed an Unrestricted Grant Agreement with Erasmus University Medical Center (“EUMC”) pursuant to which EUMC will use its best efforts to diligently carry out immune monitoring in pancreatic cancer patients.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315223011560/0001493152-23-011560-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Erasmus University Medical Center"},{"label":"Effective","value":"2023-04-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}